EGFR and neoplasm: Therapeutic benefit to EGFR TKI in NSCLC models and patients is linked to rapid changes in glycolysis with EGFR TKI.23,43 To determine whether osimertinib can reduce 18F-FDG uptake and drive tumor responses in an intracranial model of EGFR-mutant NSCLC, we implanted EGFR exon 19 deleted PC9 cells into the brains of NSG mice.